Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC
Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC
Not yet recruiting · NCT07663747 · Registry updated 2026-06-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC | Urothelial Bladder Cancer | Not yet recruiting | Phase 2 | 2026-06-25 | NCT07663747 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Astellas Pharma Inc | 43 |
| Merck Sharp & Dohme LLC | 650 |
| The Netherlands Cancer Institute | 113 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Antoni van Leeuwenhoek Ziekenhuis | Amsterdam | Netherlands | 6 |
| Leiden University Medical Center Leiden (LUMC) | Leiden | Netherlands | 1 |
| University Medical Center Utrecht(UMCU) | Utrecht | Netherlands | 1 |